文献速递急性肾损伤

老药作为抗铁死亡剂通过清除脂质过氧自由基抑制器官损伤包括AKI

Drugs Repurposed as Antiferroptosis Agents Suppress Organ Damage, Including AKI, by Functioning as Lipid Peroxyl Radical Scavengers.
PubMed 文献 · J Am Soc Nephrol · 2019-11-25

该研究通过细胞实验筛选细胞色素P450底物药物,发现利福平、异丙嗪、奥美拉唑等多种FDA批准药物具有抗铁死亡作用,机制为清除脂质过氧自由基而非其他自由基。这些药物在多种细胞类型中发挥抗铁死亡活性,并在小鼠顺铂诱导AKI和LPS/半乳糖胺诱导肝损伤模型中减轻损伤。

要点

  • 多种FDA批准药物(如利福平、异丙嗪、奥美拉唑等)具有抗铁死亡活性。
  • 抗铁死亡药物效应与清除脂质过氧自由基密切相关,与其它自由基无关。
  • 这些药物在顺铂诱导AKI小鼠模型中改善肾损伤并抑制组织脂质过氧化。

核心结论

  • 升高的脂质过氧自由基水平可触发铁死亡,清除脂质过氧自由基的药物有助于控制包括AKI在内的铁死亡相关疾病。

研究设计与样本

  • 研究采用基于细胞的实验筛选细胞色素P450底物化合物,鉴定具有抗铁死亡活性的药物,并探究其机制。
  • 使用电子顺磁共振-自旋捕获方法和荧光探针NBD-Pen评估自由基清除活性。
  • 在顺铂诱导AKI小鼠模型和LPS/半乳糖胺诱导肝损伤小鼠模型中评估药物的治疗效力。

主要发现

  • 鉴定出多种FDA批准药物和激素具有抗铁死亡特性,包括利福平、异丙嗪、奥美拉唑、吲哚-3-甲醇、卡维地洛、普萘洛尔、雌二醇和甲状腺激素。
  • 抗铁死亡药物效应与清除脂质过氧自由基密切关联,但与其它自由基的相互作用无显著关系。
  • 升高的脂质过氧自由基水平与铁死亡发生相关,已知铁死亡抑制剂如ferrostatin-1也作为脂质过氧自由基清除剂发挥作用。
  • 这些药物在多种细胞类型(包括肾小管、足细胞和肾成纤维细胞)中发挥抗铁死亡活性。
  • 在小鼠中,这些药物改善AKI和肝损伤,同时抑制组织脂质过氧化并减少细胞死亡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ferroptosis, nonapoptotic cell death mediated by free radical reactions and driven by the oxidative degradation of lipids, is a therapeutic target because of its role in organ damage, including AKI. Ferroptosis-causing radicals that are targeted by ferroptosis suppressors have not been unequivocally identified. Because certain cytochrome P450 substrate drugs can prevent lipid peroxidation via obscure mechanisms, we evaluated their antiferroptotic potential and used them to identify ferroptosis-causing radicals. METHODS: Using a cell-based assay, we screened cytochrome P450 substrate compounds to identify drugs with antiferroptotic activity and investigated the underlying mechanism. To evaluate radical-scavenging activity, we used electron paramagnetic resonance-spin trapping methods and a fluorescence probe for lipid radicals, NBD-Pen, that we had developed. We then assessed the therapeutic potency of these drugs in mouse models of cisplatin-induced AKI and LPS/galactosamine-induced liver injury. RESULTS: We identified various US Food and Drug Administration-approved drugs and hormones that have antiferroptotic properties, including rifampicin, promethazine, omeprazole, indole-3-carbinol, carvedilol, propranolol, estradiol, and thyroid hormones. The antiferroptotic drug effects were closely associated with the scavenging of lipid peroxyl radicals but not significantly related to interactions with other radicals. The elevated lipid peroxyl radical levels were associated with ferroptosis onset, and known ferroptosis suppressors, such as ferrostatin-1, also functioned as lipid peroxyl radical scavengers. The drugs exerted antiferroptotic activities in various cell types, including tubules, podocytes, and renal fibroblasts. Moreover, in mice, the drugs ameliorated AKI and liver injury, with suppression of tissue lipid peroxidation and decreased cell death. CONCLUSIONS: Although elevated lipid peroxyl radical levels can trigger ferroptosis onset, some drugs that scavenge lipid peroxyl radicals can help control ferroptosis-related disorders, including AKI.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Mishima E, Sato E, Ito J, et al. Drugs Repurposed as Antiferroptosis Agents Suppress Organ Damage, Including AKI, by Functioning as Lipid Peroxyl Radical Scavengers. J Am Soc Nephrol. 2019. PMID: 31767624. doi:10.1681/ASN.2019060570

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。